Dupilumab combined with topical corticosteroids significantly improved the symptoms of severe atopic dermatitis (AD) in children, revealed results from a phase 3 clinical trial. According to a press release, children aged 6 to 11 years with severe AD who received dupilumab combined with topical corticosteroids showed a significant improvement in the measures of overall disease severity, skin clearing, itching and health-related quality of life compared with the use of topical corticosteroids alone.
The double-blind, placebo-controlled evaluated Dupilumab in a combination with topical corticosteroids in 367 children aged 6 to 11 years with severe AD whose disease could not be adequately controlled with topical medications. All the patients received topical corticosteroids and moisturizers for 16 weeks and were randomized to receive one of three treatment groups: dupilumab subcutaneous…
